奥沙利铂治疗原发性肝癌的临床研究进展

Clinical study progression of oxaliplatin for primary hepatic carcinoma

原发性肝癌是我国高发的恶性肿瘤,由于起病隐袭,早诊困难,确诊时大多数已达局部晚期或发生远处转移,治疗棘手,预后很差;如果仅仅采取支持治疗,患者的生存时间在亚太国家只有3-4个月,而欧美国家也不过6-9个月。对于晚期肝癌,临床上经常采用系统化疗作为姑息治疗,但是迄今缺乏标准的化疗药物和方案。奥沙利铂（OXA）作为第3代铂类药物,治疗多种消化道肿瘤疗效确切。近年来,国内外学者开展了一系列有关OXA治疗晚期肝癌的临床研究,有些已有结果且陆续发表,特别是2010年ASCO年会上新报告的EACHⅢ期试验结果令人鼓舞。本文拟对有关进展进行全面的综述和讨论,以供同行参考。

Primary hepatic carcinoma is one of high incidence malignant tumors in China.Because of its insidious onset and early diagnosis difficulty,great majority patients already have reached local advanced stage or metastasis with treatment difficult and poor prognosis at diagnosis.If adopting support treatment only,patients＇ survival time only were 3-4 months in the Asian-Pacific countries,while 6-9 months in the Europe and America countries.As for advanced primary hepatic carcinoma,there often adopt the systemic chemotherapy as palliative care clinically,but is short of the standard chemotherapy agents and regimens up to now.Oxaliplatin（OXA） is one of the 3rd generation of platinum drugs,the efficacy for digestive tract tumors is definite.In recent years,the scholars have carried out a series of clinical studies in advanced liver cancer using OXA,some already had results and reported in succession.The reports of international EACH phase Ⅲ clinical trials especially were encouraging in 2010 ASCO annual meeting.Thus we draw up to all-round summing up being in progress in connection with OXA progression and discuss to provide the reference for the collages.